Innovative Therapeutics MiNA Therapeutics specializes in gene activation technologies with a focus on developing RNAa therapeutics for rare neurodegenerative and central nervous system diseases, positioning it as a pioneer in gene-based therapies that can meet the needs of niche patient populations.

Strategic Partnerships The company has established multiple research collaborations with industry players like Nippon Shinyaku, BioMarin, and NS Pharma, creating opportunities for joint development, licensing, and commercialization of novel therapies across diverse markets.

Recent Industry Engagement Participation in the European Hematology Association 2025 Congress and dissemination of pre-clinical data highlight ongoing innovation and research leadership, signifying potential for partnerships with healthcare providers and biotech firms seeking cutting-edge therapies.

Growth Potential With a revenue range of 1M to 10M and recent strategic hires such as a new Chief Scientific Officer, MiNA is expanding its scientific expertise and operational capacity, making it a promising partner for organizations looking to collaborate on early-stage or clinical phase therapeutic development.

Technology & Infrastructure Utilizing a modern tech stack including tools like Google Maps, DocuSign, and Nginx, alongside its biotech innovations, MiNA maintains a digital infrastructure conducive to efficient project management and collaboration, providing opportunities for tech-enabled solutions or strategic integrations.